Document Detail


Role of rHuEpo on blood transfusions in preterm infants after the fifteenth day of life.
MedLine Citation:
PMID:  9783307     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The specific aim of the study was to assess the safety and efficacy of recombinant human erythropoietin (rHuEpo) in reducing the need for blood transfusions in preterm infants after the 15th day of life. Between 1 October 1994 and 1 October 1995, 107 preterm infants, gestational age < or = 34 weeks, were admitted to the Neonatal Intensive Care Unit and received rHuEpo subcutaneously, 900 U/kg week-1, 3 times weekly, supplemented with iron and vitamin E. Treatment was started at 8 days of life and lasted from a minimum of 6 weeks to a maximum of 3 months. A total of 116 preterm infants of the same gestational age, admitted to the Neonatal Intensive Care Unit from 1 January 1992 to 31 December 1992, served as controls. Entry criteria were gestational age < or = 34 weeks and no major congenital malformation. There were no differences in routine care between the two groups. Hematological measurements and transfusion requirements were followed during therapy. The infants were divided into two groups according to birth weight (< 1500 g and > or = 1500 g), and for each group the number of patients who received blood transfusions and when blood transfusions occurred, before or after the 15th day of life, was recorded. There was a statistically significant difference only for transfusions carried out after the 15th day of life (p < 0.002). No adverse effects attributable to rHuEpo during the treatment were noted. The results indicate that early rHuEpo treatment, in combination with iron supplements, is effective in reducing the need for blood transfusions in preterm infants after the 15th day of life.
Authors:
M Testa; A Reali; M Copula; B Pinna; F Birocchi; C Pisu; F Chiappe
Related Documents :
21234187 - Sudden cardiac death in children and adolescents (excluding sudden infant death syndrome).
10639207 - Severe allergic bronchopulmonary aspergillosis in an infant with cystic fibrosis and he...
21540327 - Agreement on cause of death between proxies, death certificates, and clinician adjudica...
571337 - Late anaemia in infants with rhesus haemolytic disease treated with intensive photother...
17570067 - Pituitary apoplexy during treatment of cystic macroprolactinomas with cabergoline.
16372237 - Enema prior to labor: a controversial routine in taiwan.
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  Pediatric hematology and oncology     Volume:  15     ISSN:  0888-0018     ISO Abbreviation:  Pediatr Hematol Oncol     Publication Date:    1998 Sep-Oct
Date Detail:
Created Date:  1999-01-07     Completed Date:  1999-01-07     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8700164     Medline TA:  Pediatr Hematol Oncol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  415-20     Citation Subset:  IM    
Affiliation:
Istituto di Patologia e Terapia Intensiva Neonatale, Università di Cagliari, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anemia, Neonatal / prevention & control*
Blood Transfusion / utilization*
Erythropoietin, Recombinant / adverse effects,  therapeutic use*
Female
Gestational Age
Humans
Infant, Newborn
Infant, Premature, Diseases / therapy*
Male
Risk Factors
Chemical
Reg. No./Substance:
0/Erythropoietin, Recombinant

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Fever and neutropenia in children with cancer in one pediatric hospital in Argentina.
Next Document:  Familial medulloblastoma.